85results about How to "Suitable for oral" patented technology

The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

The present invention relates to the Bifidobacterium CECT 7765 strain, to its cell components, metabolites, and secreted molecules, to the combinations thereof with other microorganisms, and to compositions comprising the aforementioned products, as well as to the use of a strain of the Bifidobacterium pseudocatenulatum species, or to using the CECT 7765 strain for the prevention and/or treatment of obesity, overweight, hyperglycemia and diabetes, preferably type 2 diabetes mellitus, hepatic steatosis or fatty liver, dyslipidemia, metabolic syndrome, immune system dysfunction associated with obesity and overweight; and an unbalanced composition of the intestinal microbiota associated with obesity and overweight.

Disclosed are packaged compositions comprising an aseptically sterilized container and a sterilized, concentrated, nutritional liquid emulsion that is aseptically packaged and sealed within the container. Also disclosed are methods for making and using the packaged compositions. In some embodiments, the aseptically packaged, concentrated, nutritional liquid emulsions have a desirable flavor and aroma and have increased emulsion stability.

The present invention relates to veterinary compositions in a form of an orally deliverable tablet, and more particularly to a controlled-release composition that provides sufficiently long duration to permit once daily administration.

The invention relates to glycyrrhetinic acid solid lipid nanoparticles and a preparation method for the same, belonging to the field of medicinal preparation. The main ingredients of the glycyrrhetinic acid solid lipid nanoparticles disclosed by the invention comprise active raw material glycyrrhetinic acid, medicinal phospholipid, a lipid material and a surfactant. The glycyrrhetinic acid solid lipid nanoparticle solution and the freeze-dried powder injection thereof prepared by the preparation method disclosed by the invention are small in particle diameter, high in entrapment efficiency, good in stability and capable of being used for a plurality of administration routes such as oral administration and injection administration. The glycyrrhetinic acid solid lipid nanoparticles disclosed by the invention can reduce dosage, enhance curative effect and reduce the toxic and side effects of medicine, as well as are suitable for treating a plurality of diseases such as hepatitis, liver cancer, lung cancer, ovarian cancer, gastritis, gastric cancer, leukaemia and aids.

The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.

The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.

The invention discloses a medicine composition for treating diabetes. The medicine comprises the following components in parts by weight: 5-15 parts of longan seeds, 5-15 parts of lichee seeds, 5-10 parts of mulberry, 3-8 parts of pawpaw seeds, 3-10 parts of radix astragali and 5-10 parts of rhizoma polygonati. The components of the formulation of the medicine composition for treating diabetes are simple and scientifically, rationally formulated, the medicine has remarkable efficacy, short course, small toxic and side effect and long efficacy, is suitable for diabetic patients of variable types for administration, is suitable for oral administration, and is convenient, safe and reliable.

The invention discloses an oral emulsion rich in [alpha]-linolenic acid. The oral emulsion is prepared from the following components in percentage by weight: 1-25% of plant oil containing the [alpha]-linolenic acid, 1-25% of an emulsifier, 0.1-20% of adjuvants, 0.001-5% of an antioxidant, 0-1.5% of flavoring agent and the balance of purified water; and the plant oil containing the [alpha]-linolenic acid is extracted from the following components in parts by weight: 20-25 parts of eucommia ulmoides oliver seeds, 10-15 parts of perilla seeds, 10-15 parts of kiwi fruit seeds, 12-17 parts of peony seeds, 10-16 parts of linseed and 7-12 parts of Chinese prickly ash seeds. The invention also discloses a preparation method of the oral emulsion rich in the [alpha]-linolenic acid. The oral emulsion containing the [alpha]-linolenic acid prepared by the invention is stable in ingredient, high in bioavailability, free from toxic and side effects, obvious in curative effect, broad in application to indications and obvious in social and economic values, and bad smell and taste of the oil can be masked.

Composition comprising leucine, isoleucine, valine, threonine and lysine for use in prophylactic and/or therapeutic treatment of renal disorders in a subject, preferably an elderly subject.

The invention relates to flumatinib mesylate crystal form B and a preparation method and the use thereof. One crystal form of the flumatinib mesylate, the preparation method thereof, medicine combination of the compound and with treatment effective quantity and application of the crystal form in preparation of medicine for treating chronic myelogenous leukemia are further provided.

The invention belongs to the technical field of medicines and particularly relates to an artemether oral micro-emulsion in-situ gel and a preparation method thereof. The artemether oral micro-emulsionin-situ gel is prepared from the following components of 0.1-0.8% of artemether, 0.9-7.2% of oil phases, 0.4-12% of surfactants, 0.4-12% of cosurfactants, 0.23-0.3% of in-situ gel substrates, 0-0.1%of adhesives and the balance water. The average particle size of emulsion drops of the artemether oral micro-emulsion in-situ gel is 20.90 nm, the emulsion drops are uniform in size, the solubility and releasing rate of the artemether can be increased, and the artemether oral micro-emulsion in-situ gel is stable at the room temperature; the artemether oral micro-emulsion in-situ gel is low in viscosity and good in flowability, the gel is formed immediately in a stomach after oral administration, the detention time of the artemether in the stomach can be prolonged, treatment of a stomach cancerand improving of the bioavailability of the artemether are facilitated; and the preparation technique is easy, operation and filling are easy, and industrial production is facilitated.

L-carnitine calcium fumarate and its preparation and applications are disclosed in the present invention. Having good water solubility as well as better and stronger nutritious and treating functions than the corresponding inner salts, the L-carnitine calcium fumarate as proposed having the advantages of being non-hygroscopic, stable in chemical property, and suitable for oral administration. A preparing method is as follow: fumaric acid is suspended in water and calcium base is added. The resulting mixture is heated up to 70˜90° C. and kept under stirring for 2˜8 hours, and then concentrated under reduced pressure. The resulting dried substance is added into ethanol, and the mixture is vigorously stirred. The inner salt of L-carnitine is added, and the mixture is reacted for 1-6 hours at 60˜70° C. and then cooled for 2˜8 hours. L-carnitine calcium fumarate is obtained by filtration.

The invention relates to a traditional Chinese medicine composition for treating chronic prostatitis and a preparation method thereof. The traditional Chinese medicine composition is prepared from thefollowing raw materials in parts by weight: 8 to 12 parts of cortex eucommiae chlorogenic acid, 6 to 10 parts of cortex cinnamomi polyphenol, 13 to 17 parts of oyster peptide, 8 to 12 parts of maca,8 to 12 parts of cordyceps militaris, 13 to 17 parts of silk peptide, 2 to 6 parts of herba abelmoschi esculenti, 2 to 6 parts of cortex pausinystaliae macroceras, 2 to 6 parts of catuaba, 2 to 6 parts of herba epimedii, 2 to 6 parts of herba gynostemmatis, 2 to 6 parts of herba rhodiolae, 2 to 6 parts of radix salviae miltiorrhizae and 2 to 6 parts of semen persicae. The traditional Chinese medicine composition disclosed by the invention is simple in preparation and remarkable in curative effect, has no side effect, is safe and effective, is low in cost and is suitable for oral administration.

The invention relates to flumatinib mesylate crystal form A and a preparation method and the use thereof. Specifically, one crystal form of the flumatinib mesylate, the preparation method thereof, medicine combination of the compound and with treatment effective quantity and application of the crystal form in preparation of medicine for treating chronic myelogenous leukemia are further provided.